Lada Leyens

发表

Working towards personalization in medicine: main obstacles to reaching this vision from today's perspective.

A. Brand, K. Satyamoorthy, D. Horgan, 2014, Personalized medicine.

Personalized Medicine: What's in it for Rare Diseases?

A. Brand, M. Reumann, Lada Leyens, 2017, Advances in experimental medicine and biology.

Clinical Trials, Data Protection and Patient Empowerment in the Era of the New EU Regulations

A. Gorini, G. Pravettoni, D. Horgan, 2015, Public Health Genomics.

Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods

A. Brand, Lada Leyens, 2016, Public Health Genomics.

The COVID-19 pandemic as a catalyst for innovation: a regulatory framework to assess fit-for-purpose innovative approaches in clinical research

Lada Leyens, Tracy Simkins, Nafsika Kronidou Horst, 2022, Trials.

Use of big data for drug development and for public and personal health and care

Matthias Reumann, Angela Brand, Nuria Malats, 2017, Genetic Epidemiology.

HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome

A. Fassati, P. Cherepanov, Lada Leyens, 2009, Retrovirology.

An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe

Denis Horgan, Ralf Sudbrak, Angela Brand, 2014, Public Health Genomics.

Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy

Manousos E. Kambouris, Vita Dolzan, Alessio Squassina, 2016, Public Health Genomics.

Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine

A. Brand, Lada Leyens, Ø. Melien, 2015, Public Health Genomics.

Developing a Novel Measurement of Sleep in Rheumatoid Arthritis: Study Proposal for Approach and Considerations

R. J. Mather, Luis Garcia-Gancedo, Michelle Crouthamel, 2021, Digital Biomarkers.

Bridging communities in the field of nanomedicine

Thierry Bastogne, Valérie Zuang, Patrick Boisseau, 2019, Regulatory toxicology and pharmacology : RTP.

Modified study designs to expand treatment options in personalised oncology: A multi-stakeholder view

K. Rufibach, A. Krämer, L. Mileshkin, 2023, European Journal of Cancer.

Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research

B. Carleton, Lada Leyens, R. Syme, 2015, Public Health Genomics.

Reverse Engineering of Digital Measures: Inviting Patients to the Conversation

B. Vereijken, I. Clay, J. Goldhahn, 2023, Digital biomarkers.

Why Language Matters in Digital Endpoint Development: Harmonized Terminology as a Key Prerequisite for Evidence Generation

Lada Leyens, Carrie A. Northcott, Lesley Maloney, 2024, Digital biomarkers.

Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration

Lada Leyens, John Batchelor, Erwin De Beuckelaer, 2024, Expert review of pharmacoeconomics & outcomes research.